Cai, H.; Zheng, R.; Wu, N.; Hu, J.; Wang, R.; Chi, J.; Zhang, W.; Zhao, L.; Cheng, H.; Chen, A.;
et al. Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition. Pharmaceutics 2023, 15, 2377.
https://doi.org/10.3390/pharmaceutics15102377
AMA Style
Cai H, Zheng R, Wu N, Hu J, Wang R, Chi J, Zhang W, Zhao L, Cheng H, Chen A,
et al. Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition. Pharmaceutics. 2023; 15(10):2377.
https://doi.org/10.3390/pharmaceutics15102377
Chicago/Turabian Style
Cai, Hua, Rongrong Zheng, Ningxia Wu, Jiaman Hu, Ruixin Wang, Jianing Chi, Wei Zhang, Linping Zhao, Hong Cheng, Ali Chen,
and et al. 2023. "Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition" Pharmaceutics 15, no. 10: 2377.
https://doi.org/10.3390/pharmaceutics15102377
APA Style
Cai, H., Zheng, R., Wu, N., Hu, J., Wang, R., Chi, J., Zhang, W., Zhao, L., Cheng, H., Chen, A., Li, S., & Xu, L.
(2023). Chimeric Peptide Engineered Nanomedicine for Synergistic Suppression of Tumor Growth and Therapy-Induced Hyperlipidemia by mTOR and PCSK9 Inhibition. Pharmaceutics, 15(10), 2377.
https://doi.org/10.3390/pharmaceutics15102377
